MedTrace Logo

Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

NCT02109315 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-02-15

No results posted yet for this study

Summary

To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Vitamine C

C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min

DRUG

Liraglutide 6 mg

Liraglutide endovenous de 0.6 mg. one time a day

Sponsors & Collaborators

  • Anna Cruceta

    lead OTHER

Principal Investigators

  • Antonio Ceriello A Ceriello, MD · Hospital clínic i provincial de Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02109315 on ClinicalTrials.gov